NTELOS Holdings Corp. (NTLS) Misses Q1 EPS by 24c

NTELOS Holdings Corp. (NASDAQ: NTLS) reported Q1 EPS of $0.06, $0.24 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $122.1 million versus the consensus estimate of $125.1 million.

Subscriber Highlights

Total Subscribers

• Total subscribers were 468,000 as of March 31, 2014, compared to 451,000 for the same period of 2013;
• Total subscriber gross additions for the first quarter 2014 were 45,400, compared to 48,500 for the same period of 2013; and
• Total net subscriber additions for the first quarter 2014 were 3,400, compared to 11,400 for the same period of 2013.

Postpay Subscribers

• Postpay subscriber gross additions for the first quarter 2014 were 20,200, compared to 20,200 for the first quarter 2013 and 28,700 for the fourth quarter 2013;
• Net postpay subscriber additions were 300 for the first quarter 2014, compared to 3,300 for the first quarter 2013 and 8,900 for the fourth quarter 2013;
• Postpay churn for the first quarter 2014 was 2.2%, compared to 1.9% for the first quarter 2013;
• ARPA increased 5% to $137.47 for the first quarter 2014, compared to $130.69 for the same period in 2013; and
• As of March 31, 2014, total postpay subscribers were 306,800.

Prepay Subscribers

• Prepay subscriber gross additions for the first quarter 2014 were 25,200, compared to 28,300 for the first quarter 2013 and 22,100 for the fourth quarter 2013;
• Net prepay subscriber additions (losses) were 3,100 for the first quarter 2014, compared to 8,100 for the first quarter 2013 and (1,400) for the fourth quarter 2013;
• Prepay churn for the first quarter 2014 was 4.6%, compared to 4.6% for the first quarter 2013; and
• As of March 31, 2014, total prepay subscribers were 161,200.

For earnings history and earnings-related data on NTELOS Holdings Corp. (NTLS) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Benchmark Reiterates Buy Rating on Jumia Technologies (JMIA)
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation